Table 2. Cell-cycle analysis of LNCaP cells treated with 1 or 5 μM ATRA, 4-HPR or RAMBAs.
| Treatment | G0/G1 (%) | S (%) | G2/M (%) | Sub-G1 (%) |
|---|---|---|---|---|
| Control | 82.78 | 15.01 | 2.20 | 9.02 |
| ATRA (5 μM) | 77.74 | 9.84 | 12.42 | 13.64 |
| 4-HPR (1 μM)a | 79.53 | 9.18 | 12.03 | 7.52 |
| VN/14-1 (5 μM) | 82.59 | 7.26 | 10.15 | 17.88 |
| VN/50-1 (5 μM) | 81.33 | 11.38 | 7.30 | 17.67 |
| VN/66-1 (5 μM) | 83.80 | 11.14 | 5.07 | 14.49 |
| VN/69-1 (5 μM) | 82.66 | 11.14 | 6.20 | 13.39 |
LNCaP cells were incubated with either 1 or 5 μM ATRA, 4-HPR, or RAMBA for 6 days. LNCaP cells were then fixed and stained with propidium iodide. 104 LNCaP cells were analysed by FACScan. The percentages of cells in the G0/G1, S, and G2/M were calculated from diploid cells. The percentage of apoptotic cells (sub G0/G1) was calculated from the total number of cells minus the debris. The percentages of cells in G0/G1, S, and G2/M phases of the cell cycle as well as percentage of apoptotic cells (sub-G1) were determined using MODFIT LT software.
a
Treatment with 5 μM 4-HPR resulted in a massive amount of cell death such that no cell-cycle analysis could be performed.